
Artivion, Inc.
AORTNYSEHealthcareMedical - Devices
Previous close
$28.08
+$0.10 · +0.36%
AORT company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
60
Fair Value
Momentum
26
Weakening
Sentiment
72
Bullish
Risk resilience
36
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteArtivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- James Patrick Mackin
- Listed since
- Feb 12, 1993
- Employees
- 1,800
Market position
Day range
Current $28.08
52-week range
Current $28.08
- Open
- $27.98
- Previous close
- $27.98
- Volume
- 383.35K
- 0.52× average
- Average volume
- 734.54K
- Average daily volume
- Market cap
- 1.36B USD
- Beta
- 1.25
- Market reference 1
- 50-day average
- $24.9674
- +12.47% above average
- 200-day average
- $34.7026
- -19.08% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 2.29B USD
- P/E (TTM)
- -471.14×
- P/B (TTM)
- 3.06×
- P/S (TTM)
- 2.89×
- EV / EBITDA
- 35.96×
- Earnings yield
- 0.47%
- Free cash flow yield
- -0.04%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 62.80%
- Operating margin
- 4.00%
- Net margin
- -0.67%
- Return on equity
- 2.18%
- Return on assets
- 1.10%
- Return on invested capital
- 2.24%
Financial health
- Debt / equity
- 0.92×
- Current ratio
- 2.99×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 441.33M USD | 388.54M USD | 354M USD | 313.79M USD | 298.84M USD |
| Cost of goods sold | 170.88M USD | 139.76M USD | 124.83M USD | 111.27M USD | 101.32M USD |
| Gross profit | 270.45M USD | 248.78M USD | 229.18M USD | 202.52M USD | 197.51M USD |
| Research and development | 30.99M USD | 28.45M USD | 28.71M USD | 38.88M USD | 35.55M USD |
| Selling, general, and administrative | 212.72M USD | 192.38M USD | 208.98M USD | 157.44M USD | 169.77M USD |
| Operating expenses | 243.71M USD | 209.91M USD | 223.43M USD | 196.32M USD | 189.4M USD |
| Interest income | 763K USD | 1.47M USD | 1.08M USD | 147K USD | 79K USD |
| Interest expense | 26.58M USD | 34.28M USD | 25.3M USD | 18.22M USD | 16.89M USD |
| Depreciation and amortization | 22.46M USD | 24.21M USD | 23.08M USD | 22.44M USD | 23.98M USD |
| Operating income | 26.75M USD | 38.87M USD | 5.74M USD | 6.2M USD | 8.12M USD |
| Net income | 9.77M USD | −13.36M USD | −30.69M USD | −19.19M USD | −14.83M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 27%
- 3 beats, 8 misses, 0 met estimates
- Average EPS surprise
- -1429.42%
- 11 comparable reports
- Latest EPS result
- -0.28
- Estimate 0 · Miss by 11300.00%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$42.50
51.35% upsideRating distribution
12 ratingsRecent analyst actions
AORT peers
ETFs holding AORT
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR73.65M0.07%111.19B USD0.06%$147.31+0.64%
Vanguard Morningstar Total Stock Market ETFVTI39.26M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM32.69M0.04%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF13.19M0.01%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Growth ETFIWO12.02M0.08%15.16B USD0.24%$387.37+1.24%
iShares S&P Small-Cap 600 Growth ETFIJT11.16M0.13%8.22B USD0.18%$173.9+0.61%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM11.15M0.07%17.03B USD0.03%$57.28+0.61%
Invesco S&P SmallCap Momentum ETFXSMO6.93M0.23%3.04B USD0.36%$86.05+0.54%
iShares Core S&P Small-Cap ETFIJR- Market value
- 73.65M
- Weight
- 0.07%
- AUM
- 111.19B USD
- Expense ratio
- 0.06%
- Price / 1D
- $147.31+0.64%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 39.26M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 32.69M
- Weight
- 0.04%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 13.19M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Growth ETFIWO- Market value
- 12.02M
- Weight
- 0.08%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
iShares S&P Small-Cap 600 Growth ETFIJT- Market value
- 11.16M
- Weight
- 0.13%
- AUM
- 8.22B USD
- Expense ratio
- 0.18%
- Price / 1D
- $173.9+0.61%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM- Market value
- 11.15M
- Weight
- 0.07%
- AUM
- 17.03B USD
- Expense ratio
- 0.03%
- Price / 1D
- $57.28+0.61%
Invesco S&P SmallCap Momentum ETFXSMO- Market value
- 6.93M
- Weight
- 0.23%
- AUM
- 3.04B USD
- Expense ratio
- 0.36%
- Price / 1D
- $86.05+0.54%
Continue in GoAI
Research AORTresearch.disclaimer





